Description
Cytovir-3 Pharmacodynamics
Pharmacodynamics: Cytovir-3 is a means of etiotropic and immunostimulant therapy, it has mediated antiviral action against influenza A and B pathogens, as well as other viruses causing acute respiratory diseases.
In in vitro studies, the drug specifically suppresses (inhibits) the reproduction (replication) of SARS-CoV-2 virus, which is the causative agent of a new coronavirus infection (COVID-19).
The degree of pathogen inhibition increases with increasing drug concentration (dose-effect linearity is shown).
It reduces the severity of the main clinical symptoms of influenza and acute respiratory infections, as well as reduces the duration of the disease and contributes to its uncomplicated course.
It increases secretory immunoglobulin A (slgA) content in nasopharynx mucosa, which is the entrance gate of infection, increasing local immunoresistance to respiratory infections of viral and bacterial nature.
During prophylactic action the preparation increases potential metabolic activity of innate immunity cells (neutrophil granulocytes and monocytes) which in case of developing infection increases their ability to absorb and destroy bacterial and viral agents by increasing enzymatic (oxidative) activity, synthesis of cationic proteins and increasing number of phagocytes. At the same time, the initial state of metabolic activity of innate immunity cells in the absence of infectious agents does not change, being within normal values.
Bendazole induces in the body the production of endogenous interferon, has immunomodulatory effect (normalizes the body’s immune response to various infectious agents). Enzymes induced by interferon in cells of various organs inhibit viral replication.
Alpha-glutamyl-tryptophan (thymogen) is a synergistic immunomodulatory effect of bendazole, normalizing the T-cell link of immunity.
Ascorbic acid activates humoral immunity, normalizes capillary permeability, thereby reducing inflammation, exhibits antioxidant properties, neutralizing oxygen radicals that accompany the inflammatory process, increases the body’s resistance to infection.
Pharmacokinetics: when administered orally the drug is completely absorbed from the gastrointestinal tract. Bioavailability of bendazole is about 80%, alpha-glutamyl-tryptophan – no more than 15%, ascorbic acid – up to 90%. Metabolites of ascorbic acid and bendazole are excreted with urine. Alpha-glutamyl-tryptophan under the influence of peptidases is split into L-glutamic acid and L-tryptophan, which are used by the body in peptide synthesis.
- Inside, 30 minutes before a meal. Single dose for adults and children over 6 years – 1 capsule.
- For treatment:
- One capsule 3 times a day for 4 days.
- For prevention:
- – In direct contact with a patient with influenza and other acute respiratory infections, one capsule 3 times a day for 4 days.
- – During epidemic upsurge of influenza and other acute respiratory viral infections, one capsule 1 time a day for 12 days.
- Prophylactic courses, if necessary, repeated in 3 weeks (until the normalization of the epidemic situation).